This week, the Journal of the American Medical Association published the first data of its kind around COVID-19 vaccination among solid organ transplant recipients. The study, which was authored by researchers at @Johns Hopkins University, found that people who are post-transplant are shown to have a much lower immune response to the vaccine.
Al Faro, the vice president of clinical affairs at the CF Foundation, discusses with Sarah Alspach, chief communications officer at the CF Foundation, what this update means for members of the cystic fibrosis community who have received a solid organ transplant.
0:26 | What does the Johns Hopkins University study mean for people who have received a solid organ transplant, including lung transplant recipients with cystic fibrosis?
2:12 | What do we know about the study participants, and were there any differences in how they responded to the COVID-19 vaccines?
3:16 | What does this mean for people with cystic fibrosis who have received a solid organ transplant, like a double lung transplant? Should they follow the recent CDC guidance about what fully vaccinated people can do?
5:36 | The study looked at participants after they had received the first dose of the vaccine. Do the researchers from John Hopkins University plan to do a follow-up, once post-transplant recipients have received the second dose of the COVID-19 vaccine?
6:11 | How can other immunocompromised groups participate in research about COVID-19 vaccines?
6:48 | Should people who are post-transplant still get vaccinated?
Originally recorded March 17, 2021
Learn more about the national vaccine research study for transplant recipients: https://transplantvaccine.org/